Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Overview
CoChat Summary
## TL;DR
The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.
## Key findings
- The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
- At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
- In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
- Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).
## Methods
- Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
- The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
- Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.
## Limitations
- The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
- The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
- Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Standard risk | 182/266 (68.4) | 234/264 (88.6) | | 3.60 (2.27–5.70) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Non-IgG | 73/96 (76.0) | 72/78 (92.3) | | 3.78 (1.45–9.83) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| ≥65 years | 62/87 (71.3) | 77/94 (81.9) | | 1.83 (0.91–3.68) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Male | 94/205 (45.9) | 150/211 (71.1) | | 2.90 (1.94–4.35) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| <65 years | 186/267 (69.7) | 235/261 (90.0) | | 3.94 (2.43–6.37) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 11
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The quadruplet regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) has recently emerged as standard of care option for initial therapy in transplant eligible patients with newly diagnosed myeloma.101,111”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The role of daratumumab in patients who received it as part of frontline therapy is unclear.101,152”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Research works printed but not linked: 1
- 7. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016;43:676-81.
Cited by
Items 501–589 of 589
Does minimal residual disease matter in t(11;14) myeloma?
Touzeau, C., & Corre, J. (2026) · Blood · doi:10.1182/blood.2025032941
Improving control arms in 2026 US myeloma trials
Ding, K., Kunesh, J., Neupane, K., & Mohyuddin, G. R. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020329 · Cited by 1
Sheng, X., Zheng, Q., Xiang, J., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1813060
Liu, Y., Mo, C. C., Midha, S., Hartley-Brown, M. A., Lee, H. C., Franz, J. K., Nadeem, O., Nicholson, T., Salman, T. J., Fortune, A., et al. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2660911
“…therapies are the current standard of care in NDMM, as they build on the superb activity of triplets, and are likely to continue to be a mainstay of MM therapy, as supported by improved survival outcomes in IMROZ, BENEFIT, PERSEUS (daratumumab-VRd), and CEPHEUS (daratumumab-VRd) [71,76,98,99].”
Self-citationChen, W., Cai, Z., Chim, C. S., Chng, W. J., Du, J., Fu, C., Gao, W., Hanamura, I., Hou, J., Huang, J. S.-Y., et al. (2026) · Clinical Hematology International · doi:10.46989/001c.160933 · Cited by 2
Aydın, Ö., Şahin, O., Akça, E., Kürekçi, D. D., Aktimur, S. H., Kelkitli, E., & Turgut, M. (2026) · Cancers · doi:10.3390/cancers18101570
“The incorporation of monoclonal antibodies such as daratumumab into induction and maintenance regimens has led to deeper responses and improved survival outcomes [6,7].”
Elgendy, S. O., Imam, M. S., Alshehri, A. A., Alsufyani, W. Z. A., Albogami, M., Almalki, S. A. S., Alkhaldi, M. N. M., Samarkandi, M. W. A., Alibrahim, D. T. Y., Hakami, F. A. H., et al. (2026) · BioMedInformatics · doi:10.3390/biomedinformatics6030028
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
Fuentes-Lacouture, M. C., Nandana, D., Ramasamy, K., & Thakurta, A. (2026) · FEBS Journal · doi:10.1111/febs.70599
“Rd [Isa-KRd] (MIDAS study), and Isa-VRd (IMROZ study) have improved clinical outcomes with estimated median PFS between 100 and 200 months (median not reached) across these regimens from frontline therapy [70 – 73].”
Clinical implications of minimal residual disease monitoring in multiple myeloma
Yoroidaka, T. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04229-8
“In major clinical trials comparing the efficacy of triplet and quadruplet regimens, MRD has been measured at these recommended time points, providing robust prognostic information [28, 35, 37, 41–43, 75 ].”
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy
Morgan, G. J., Lee, D. D., Joseph, N. S., Lonial, S., Rodríguez‐Otero, P., & San-Miguel, J. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-517494
Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma
Xu, H., Wu, W., Jiang, Y., 王金环, Zhai, Y., & Zhao, Z. (2026) · Cancer Medicine · doi:10.1002/cam4.71985
Self-citationHansen, D. K., Mateos, M., & Costa, L. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019699
Zweegman, S., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Marti, J., Basu, S., Cohen, Y. C., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019937
“15,33,34 Of note, in the primary analysis of CEPHEUS, there was a reduction in the risk of disease progression or death with D-VRd over VRd in patients with high cytogenetic risk (HR, 0.88; 95% CI, 0.42-1.84), 16 and, as presented here, this reduction was greater in patients with high cytogenetic…”
InfluentialSelf-citationMeasurable residual disease in myeloma: a MyRiaD of findings
Puig, N. (2026) · Blood · doi:10.1182/blood.2025032857
D-VRD induction and autologous transplant in patients ≥70 years
Pasvolsky, O., Marcoux, C., Milton, D. R., et al. (2026) · Blood Cancer Journal · doi:10.1038/s41408-026-01522-x
“…progression-free survival (PFS) in newly diagnosed multiple myeloma (MM), as demonstrated in the GRIFFIN and PERSEUS trials, both of which evaluated daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRD) induction followed by autologous hematopoietic cell transplantation (autoHCT) [1, 2].”
Jazowski, S. A., Wood, W. A., & Dusetzina, S. B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00087
Bertuglia, G., Nicola, A. D., Gay, F., Larocca, A., Bruno, B., & D’Agostino, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1822419
Self-citationTheprungsirikul, P. P., Al-Musa, A., Bar, N., Browning, S. L., Parker, T., & Neparidze, N. (2026) · Cancers · doi:10.3390/cancers18121899
“…and PERSEUS trials demonstrated that adding DARA to bortezomib, lenalidomide, and dexamethasone (D–VRD) significantly improved stringent complete response (sCR) rates, MRD negativity, and progression-free survival (PFS) in transplant-eligible (TE) NDMM patients compared to VRD alone [15–17].”
Improved survival in patients admitted to ICU with multiple myeloma: a retrospective cohort analysis
Nakaa, S., Caillot, L., Chermak, A., Kemp, H., Harel, S., Darmon, M., Azoulay, É., & Lemiale, V. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2026.100100
“These complications may arise from the MM itself — such as hypercalcemia, kidney failure, and sepsis — or from treatment-related toxicity, including cytopenia, infections, and cardiopulmonary complications [1,7,10].”
Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions
Wang, G., Gao, H., Xie, T., & Zi, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116996
Ludwig, H., Terpos, E., Gay, F., van de Donk, N. W. C. J., Bernhard, S., Engelhardt, M. M., Cook, G., Schjesvold, F. H., Einsele, H., Jackson, G., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70397
“The PERSEUS [46] and GRIFFIN [47] trials compared dara-tumumab plus lenalidomide continuous therapy stopping after”
Self-citationPuertas, B., Padilla, I., Alejo, E., Serra-Toral, F., García‐Mateo, A., López-López, R., Bárez, A., Alonso, J. M., Aguilar-Franco, C., de Cabo, E., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70606
“The likelihood of detecting aMRD is markedly lower in patients who achieved ≥VGPR prior to HSC collection, and with quadruplet induction regimen over 90% of patients reach this response, 15,32–34 dramatically reducing the probability of aMRD+ve.”
MRD in multiple myeloma: Moving from “minimal” to “measurable”
Cassano, R. C., Banerjee, R. K., Afrough, A., Portuguese, A. J., Thakur, R., Cicero, K. I., Kwok, M., Foster, L. H., Buda, G., Meletath, S. K., et al. (2026) · Blood Reviews · doi:10.1016/j.blre.2026.101413
Use of daratumumab in first-line therapy for multiple myeloma
Voytsekhovskiy, V. V., Esenina, T. V., Filatova, E. A., et al. (2026) · Bulletin physiology and pathology of respiration · doi:10.36604/1998-5029-2026-100-145-155
Lee, N., Kim, S., Lee, Y., Park, S. Y., Cho, H., Byun, J. M., Koh, Y., Hong, J., Shin, D.-Y., Min, C.-K., et al. (2026) · Blood Research · doi:10.1007/s44313-026-00149-y
“These findings are concord-ant with recent trials investigating D-VRd (GRIFFIN and PERSEUS), which established quadruplet induction as a new standard of care in transplant-eligible populations [21, 22].”
Advancements in multiple myeloma treatment: Integrating quadruplet and dual antigen CAR-T therapy
Khan, M., Alfano, D., & Gupta, A. (2026) · iScience · doi:10.1016/j.isci.2026.116509
Mina, R., Terpos, E., Cani, L., Nooka, A. K., Trudel, S., Voorhees, P., Mian, H. S., Dhakal, B., Usmani, S. Z., Richter, J., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.06.014
Self-citationLiu, L., Ruan, M., Wang, M., Pu, L., Ling, Z., Bo, J., & Zhu, K. (2026) · BMC Cancer · doi:10.1186/s12885-026-16414-3
“This may be because patients with advanced-stage tumors exhibit enhanced secretion of inflammatory factors from tumor cells, increased tumor burden, and an inflammatory bone marrow microenvironment [23].”
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison
Pasvolsky, O., Marcoux, C., Milton, D. R., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2688555
“Quadruplet induction regimens incorporating anti-Cd38 antibodies have been associated with deeper responses and longer progression-free survival (PFS) compared to triplet regimens in randomized clinical trials [1,2].”
Dung, N. N., Trang, P. T. T., Anh, P. T. N., Le Nhu, Y., Tùng, N. Q., & Anh, N. V. B. (2026) · International Journal of Surgery Case Reports · doi:10.1097/rc9.0000000000000601
“Despite these unfavorable features, our patient achieved CR after four cycles of daratumumab-based quadruplet therapy (D-VRd), in line with current international recommendations for high-risk MM [13] .”
Huang, I. J., Baek, G., Wu, Q. V., Chen, G. Z., Marzouk, O., Cohen, J., Kwok, M., Banerjee, R. K., Cicero, K. I., Basom, R., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02955-5
“In parallel, the phase 3 PERSEUS trial showed that daratumumab-based induction and consolidation followed by daratumumab-lenalidomide maintenance signi fi cantly improved PFS compared with lenalidomide maintenance alone [27].”
Pathak, S., Ahmed, R., Nagy, N., Lee, S., Bader, C. S., Regmi, S., Iliopoulou, B. P., Chen, P.-I., Gupta, B., Villar‐Prados, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.27.734105
“The clinical efficacy of CD38 targeting antibodies has been primarily studied for the treatment of plasma cell dyscrasias, where the excessive production of non-functional autoantibodies can lead to direct organ toxicity and paraneoplastic autoimmune disorders 26,27 .”
Tan, C. R., Gordan, L., Richter, J. R., Dileo, R., Mewawalla, P., Larson, S., Davies, F., Oveisi, D. R., Gupta‐Werner, N., Medhekar, R., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2698699
“[6].”
InfluentialSolovev, M. V., Mendeleeva, L. P., Soloveva, M. V., Samoilova, O. S., Davydkin, I. L., Алексеевич, Г. Т., Kaplanov, K. D., Kaporskaya, T. S., Shelekhova, T. V., Volodicheva, E. M., et al. (2026) · Гематология и трансфузиология · doi:10.35754/0234-5730-2026-71-2-142-160
Miller, K. C., Fei, T., Ramos, R. J. J. F., Castro, F., Gradíssimo, A., Block, T. J., Hamadeh, I. S., Maclachlan, K. H., Hultcrantz, M. L., Hassoun, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0752
Evolution of real-world frontline treatment patterns in multiple myeloma
Lazzaro, A., Nannini, K., Yildirim, C., Huhmann, L., Culnan, J., Corrigan, J. K., Elbers, D. C., Do, N., Brophy, M. T., Munshi, N. C., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019843
Kecman, N., Sretenovic, A., Mitrovic, M., Bukumirić, Z., Tanović, I., Vukosavljevic, N., Jovanović, J., Fekete, M. D., & Bila, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1869023
De-escalation trials in multiple myeloma: past, present and future
Mian, H. S., Costa, L. J., Mohty, M., Garfall, A. L., & Rajkumar, S. V. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01186-3
“One of the most practice-changing applications of MRD-adapted de-escalation, currently incorporated into routine clinical practice, has emerged from the phase III PERSEUS trial 14 .”
InfluentialChemotherapy and targeted therapy
Janžič, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00057-6
Uyemura, B. S., & Callander, N. S. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.07.014
Puła, B., Ryżewska, W., Handziuk, A., Tyczyńska, A., & Kubicki, T. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2715442
“Daratumumab quad-ruplet therapy with bortezomib, lenalidomide, and dexamethasone is now approved for transplant-ineligible and transplant-eligible patients, based on the CEPHEUS and PERSEUS trials [53,54].”
Identification of Marker Immunoglobulin Rearrangements for Use by HAT-PCR in Myeloma
Hughes, E., & Morley, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167128
Jiang, H., Li, Q., Wang, L., Dou, X., Leng, Q., Miao, M., Yang, Y., Zhang, M., Li, Y., Li, J., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08637-6
“Clinical trials have demonstrated that VRd achieves high rates of overall response rate (ORR) of 82–90%, alongside a 48-month progression-free survival (PFS) rate of 67.7%, which significantly outperforms conventional chemotherapy [6, 7].”
InfluentialSelf-citation2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Beksaç, M., Mastanzade, M. G., Değirmenci, B. B., Oluk, B., Sağlam, B., Özlük, D. Ö., Cengiz, E., Alhan, F. N., Dikici, H. Z., Uygun, K. Y., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.08.008 · Cited by 1
Self-citationZweegman, S., Usmani, S. Z., Hungria, V. T. D. M., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03111-0
Self-citationMultiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Alvaro, M. E., Martino, E. A., Caserta, S., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Morabito, F., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1934257
“In PERSEUS, daratumumab plus VRd followed by daratumumab-lenalidomide maintenance signi fi cantly improved PFS and produced higher MRD-negative rates than VRd alone, with MRD assessed by NGS according to IMWG criteria (44).”
Suzuki, K., Hanamura, I., Takamatsu, H., Kawamura, K., Sakaida, E., Ri, M., Kataoka, K., Hangaishi, A., Sunami, K., Saito, A., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2716453
Facon, T. T. F., Kumar, S. K., Orlowski, R. Z., Bahlis, N. J., Moreau, P., Goldschmidt, H., Basu, S., Hulin, C., Zweegman, S., Weisel, K. C., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03097-9
Self-citationDuminuco, A., Palumbo, G. A., Avella, E., Cupri, A., Garibaldi, B., Limoli, M. C., Mauro, E., Patti, S., Risata, N., Romano, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176520 · Cited by 1
“…(daratumumab–VRd versus VRd) demonstrated superior 48-month progression-free survival (84.3% versus 67.7%; HR 0.42) and far higher rates of MRD-negativity at 10 − 5 , and IsKia established an analogous benefit for isatuximab–carfilzomib–lenalidomide– dexamethasone followed by auto-HSCT [209,210].”
InfluentialHung, Y.-C., Cho, S., Chen, Y.-Y., Hsu, Y., Huang, S., Wei, C., Tsai, C., Huang, W., & Liu, C. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.08.029
Su, L., Ye, M., Peng, B., Fan, L., & Wu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787690
Crusoé, E. D. Q., Ribeiro, G., Filho, J. T. D. S., Filho, J. S., Schutz, N. P., Aranha, M. A. F., Costa, A., Neto, A. E. H., Pericole, F. V., Lima, J. S., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70775
Real World Data and Its Impact on the Management of Plasma Cell Dyscrasias
Subramanian, N. G., & Rubinstein, S. M. (2026) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-026-00787-0
“Similarly, RWD has been used to give further support to the use of daratumumab in the first line setting that was established in multiple phase 3 clinical trials, both in the intravenous and subcutaneous forms [51, 52].”
Costa, L. J. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00326-5
Yu, L., Li, C., Guo, D., & Cui, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932951
Multiples Myelom: Modernes Verständnis von Heilung geht über MRD-Negativität hinaus
Weinhold, N., Raab, M., Kortüm, M., Mai, E. K., Goldschmidt, H., Einsele, H., & Rasche, L. (2026) · Deutsches Ärzteblatt · doi:10.3238/personko.2026.09.04.01
Self-citationXue, H., Endo, T., Kadoya, K., Iwasaki, N., & Terkawi, M. A. (2026) · Bone Research · doi:10.1038/s41413-026-00576-8 · Cited by 2
Itez, G. G., & Sunguroğlu, A. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261484713 · Cited by 1
dos Anjos, A. S., Mendonça, C. V., Maradei, S. C., Rivello, J., Kaufman, J., Moreira, M. C. R., Morgado, M., Garnica, M., & Maiolino, Â. (2026) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2026.106531
Yokoyama, D., Minakata, D., Fujiwara, S., Honda, S., Tominaga, R., Noguchi, A., Furuki, S., Koyama, S., Murahashi, R., Nakashima, H., et al. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2723847
Kaiser, M., Phillip, R., Brown, S., Holroyd, A., Ferris, E., Tute, R. M. D., Roberts, S., Clayton, L. H., Bowles, K., Garg, M. K., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00286-x
Hellmig, M., & Krebs, C. F. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag299
Witteles, R. M., Zhang, B. M., Cheng, P. P., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.06.018
Wei, Y., Yang, X., Zheng, Y., & Zhang, D. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261488942
“25 Given the patient’s high-risk baseline profile described above, D-VRd would theoretically have been the optimal initial regimen.”
Xu, X., Gong, J.-H., Wang, R., Liu, T., Chen, Y.-J., Liu, J.-Y., & Li, J.-Z. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.09.005
IFM 2026 Recommendations for First-line Treatment of Newly Diagnosed Multiple Myeloma
Perrot, A., Manier, S., Hulin, C., Demarquette, H., Bobin, A., Frenzel, L., Karlin, L., Decaux, O., Mohty, M., Arnulf, B., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.002
Self-citationTreatment Decisions in Multiple Myeloma
Mouhieddine, T. H., & Anderson, K. C. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2605253 · Cited by 1
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making
Bazarbachi, A. H., Lentzsch, S., Facon, T. T. F., Harousseau, J., & Mohty, M. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00545
Blair, P., Chu, T., Robinson, A., Saja, K., Rushworth, S. A., Zwacka, R. M., & Mohr, A. (2026) · Cytokine · doi:10.1016/j.cyto.2026.157213
Osama, M., Khan, M. H., Tahir, A., Hussain, A., Iftikhar, A., Ali, A., Khan, S., Hassan, M. B., Alam, I., Khan, Z., et al. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261489040
“17,19 Minimal residual disease (MRD) negativity was significantly enhanced with daratumumab-based quadruplet therapy (RR 1.99), supporting its effectiveness in achieving deeper treatment responses.”
InfluentialLeung, O. J., Baranov, E., Isairis, P. V., et al. (2026) · Histopathology · doi:10.1111/his.70277
Lee, J. H., Kim, S., Kım, K., Ashrafi, E., Wellard, C. J., Moore, E., Chng, W. J., Chen, W., Gan, G. G., Ho, P. J., et al. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70318
Self-citationRees, M. J., Lasica, M., Kalff, A., Low, M. S. Y., Harrup, R. A., Lai, H. C., Sidiqi, M. H., Doo, N. W., Routledge, D. J. M., Hocking, J., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70851
Self-citationGu, L. C., Raval, O., Ji, X. (., Joseph, N., Hofmeister, C. C., Gupta, V. A., Parikh, R., Shah, N., Mina, R., Switchenko, J. M., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.09.013
Self-citationMinimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass.
Tamariz-Amador, L., Rodriguez-Otero, P., Manubens, A., Lasa, M., González, C., Paiva, B., & San-Miguel, J. (2026) · Cancer Journal · doi:10.1097/ppo.0000000000000846
Self-citationLonial, S., Dimopoulos, M. A., Γαβριατοπούλου, Μ., Kim, K., Min, C.-K., Oriol, A., Moreira, C. C. C., Quach, H., Qiu, L., Xia, Z., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00450-x · Cited by 1
Self-citationJoshi, A., Puliafito, B. R., Cirstea, D. D., Branagan, A. R., Gustine, J. N., Shome, R., Panaroni, C., Yee, A. J., & Raje, N. S. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000853
Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy
Lim, K. J., Pertile, H., & Spencer, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1932648
Self-citationProteostasis as a Therapeutic Backbone: Proteasome Inhibitors and Emerging Regimens
Song, Y., Theprungsirikul, P., Gullà, A., & Anderson, K. C. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000852
Usmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00401
Self-citationNtanasis‐Stathopoulos, I., Terpos, E., & Dimopoulos, M. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000845
Self-citationCrossing the Threshold to Cure in Multiple Myeloma
Sperling, A. S., & Munshi, N. C. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000855
Tailoring Therapy for Frail and Elderly Myeloma Patients
George, T., & Szalat, R. E. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000850
Younis, O. M., Göklemez, S., Awadallah, C., Atrash, S., Paul, B. A., Shaikh, H. G., Strouse, C. S., Vegel, A. J., Struble, E., Mazloom, A., et al. (2026) · Cancers · doi:10.3390/cancers18193147
Koca, T. G., Koca, N., Hunutlu, F. Ç., Yanık, A. M., Çubukçu, S., Yılmaz, R., Ersal, T., Gürsoy, V., Pınar, İ. E., Özkocaman, V., et al. (2026) · Cancers · doi:10.3390/cancers18193178
Corre, J., Lambert, J., Bobin, A., Manier, S., Perrot, A., Karlin, L., Roussel, M., Bigot, N., Benbrahim, O., Allangba, O. T., et al. (2026) · HemaSphere · doi:10.1002/hem3.70482
Self-citationDu, W., Wang, S., Song, J., & Gu, W. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261495841
Magrangeas, F., Cherkaoui, M., Bessonneau-Gaborit, V., Derrien, J., Chevalier, C., Guérin-Charbonnel, C., Diamond, B., Samur, M. K., (IFM), I. F. D. M., Hulin, C., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04692-0
Self-citation
Metadata
- Authors
- Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
- Affiliations
- University Medical Center Groningen (NL)
- The University of Sydney (AU)
- From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
- Oslo University Hospital (NO)
- Jagiellonian University (PL)
- ORCID
- Sonneveld, Pieter
- Dimopoulos, Meletios A.
- Boccadoro, Mario
- Quach, Hang
- Ho, P. Joy
- Hulin, Cyrille
- Antonioli, Elisabetta
- Leleu, Xavier
- Mangiacavalli, Silvia
- Perrot, Aurore
- Belotti, Angelo
- Broijl, Annemiek
- Gay, Francesca
- Mina, Roberto
- Katodritou, Eirini
- Schjesvold, Fredrik
- Rosiñol, Laura
- Delforge, Michel
- Roeloffzen, Wilfried
- Silzle, Tobias
- Vangsted, Annette
- Einsele, Hermann
- Spencer, Andrew
- Jurczyszyn, Artur
- Ahmadi, Tahamtan
- Liu, Yanfang
- Wang, Jianping
- Sitthi-Amorn, Anna
- Bladé, Joan
- Moreau, Philippe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-25
- Volume
- 390
- Issue
- 4
- Pages
- 301-313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389606680
- Cited by
- 599
- References
- 23
- Citations by year
- 2026: 198 · 2025: 252 · 2024: 145
- FWCI
- 123.04
- Type
- journal article
- Language
- en
- Open access
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
- MeSH terms
- Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


